BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia

Raghuram Kadari- January 21, 2023 0

BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More

Natco Pharma faces legal setback for Imbruvica generic in US

pallavi123- August 21, 2021 0

Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of ... Read More

AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study

pallavi123- June 13, 2021 0

AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More

Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment

pharmanewsdaily- August 27, 2018 0

Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA ... Read More